Raymond James & Associates Takes Position in Revvity, Inc. (NYSE:RVTY)

Raymond James & Associates bought a new position in Revvity, Inc. (NYSE:RVTY) in the 4th quarter, Holdings Channel reports. The firm bought 7,952 shares of the company’s stock, valued at approximately $869,000.

A number of other large investors have also recently made changes to their positions in RVTY. KBC Group NV bought a new stake in shares of Revvity during the 3rd quarter worth approximately $25,301,000. 2Xideas AG purchased a new stake in Revvity in the third quarter worth $20,968,000. Citigroup Inc. bought a new stake in shares of Revvity during the third quarter worth $5,548,000. Wesbanco Bank Inc. purchased a new stake in shares of Revvity during the third quarter valued at $522,000. Finally, Headinvest LLC purchased a new stake in shares of Revvity during the third quarter valued at $57,000. 86.65% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling at Revvity

In other news, insider Prahlad R. Singh sold 21,217 shares of the company’s stock in a transaction on Monday, February 5th. The stock was sold at an average price of $104.28, for a total transaction of $2,212,508.76. Following the transaction, the insider now directly owns 92,801 shares of the company’s stock, valued at $9,677,288.28. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. 0.60% of the stock is owned by insiders.

Analyst Ratings Changes

Several research analysts recently commented on RVTY shares. Evercore ISI raised shares of Revvity from an “in-line” rating to an “outperform” rating and raised their price target for the stock from $88.00 to $125.00 in a research note on Thursday, January 4th. KeyCorp lifted their price target on shares of Revvity from $110.00 to $126.00 and gave the company an “overweight” rating in a research note on Friday, February 2nd. Stifel Nicolaus boosted their price target on Revvity from $95.00 to $110.00 and gave the company a “hold” rating in a report on Friday, February 2nd. Raymond James raised their price objective on Revvity from $106.00 to $127.00 and gave the stock an “outperform” rating in a report on Friday, February 2nd. Finally, Barclays upped their target price on Revvity from $92.00 to $105.00 and gave the stock an “equal weight” rating in a report on Thursday, January 25th. Six investment analysts have rated the stock with a hold rating and six have given a buy rating to the company’s stock. Based on data from MarketBeat, Revvity has an average rating of “Moderate Buy” and a consensus price target of $118.91.

Revvity Trading Down 0.1 %

RVTY opened at $100.77 on Tuesday. The company has a current ratio of 2.07, a quick ratio of 1.77 and a debt-to-equity ratio of 0.40. The firm has a market cap of $12.45 billion, a price-to-earnings ratio of 18.32, a PEG ratio of 2.63 and a beta of 1.09. Revvity, Inc. has a 12 month low of $79.50 and a 12 month high of $135.67. The stock has a fifty day moving average price of $104.69 and a 200-day moving average price of $101.52.

Revvity (NYSE:RVTY) last announced its earnings results on Thursday, February 1st. The company reported $1.25 EPS for the quarter, topping analysts’ consensus estimates of $1.15 by $0.10. Revvity had a net margin of 25.20% and a return on equity of 7.41%. The business had revenue of $695.90 million during the quarter. As a group, equities research analysts anticipate that Revvity, Inc. will post 4.65 earnings per share for the current fiscal year.

Revvity Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, May 10th. Investors of record on Friday, April 19th will be given a dividend of $0.07 per share. The ex-dividend date of this dividend is Thursday, April 18th. This represents a $0.28 dividend on an annualized basis and a yield of 0.28%. Revvity’s payout ratio is 5.09%.

Revvity Company Profile

Revvity, Inc provides health sciences solutions, technologies, and services in the Americas, Europe, and Asia, and internationally. The Life Sciences segment provides instruments, reagents, informatics, software, subscriptions, detection, imaging technologies, warranties, training, and services. Its Diagnostics segment provides instruments, reagents, assay platforms, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market.